PDRN and Adenosine A2A Receptor Anti-Inflammatory Mechanisms (2017)

Key Findings

• PDRN exerts its primary pharmacological activity through specific binding to the adenosine A2A receptor, which activates the cAMP-PKA intracellular signaling cascade and results in potent anti-inflammatory, pro-angiogenic, and tissue-regenerative effects ^[1].
• A2A receptor activation by PDRN suppresses NF-kB nuclear translocation, significantly reducing production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-8 in multiple experimental models of tissue injury and inflammation ^[1][2].
• PDRN-mediated VEGF upregulation through the A2A pathway promotes angiogenesis in ischemic and damaged tissues, improving wound healing outcomes in both diabetic and non-diabetic models ^[1][3][4].
• The A2A receptor mechanism is pharmacologically distinct from PDRN's separate role as a nucleotide salvage pathway substrate, establishing PDRN as a dual-action biological agent ^[1][5].
• Clinical applications span wound healing, skin rejuvenation, orthopedic tissue repair, and ischemic tissue rescue, with an excellent safety profile across all documented uses ^[1].

Abstract

Squadrito et al. (2017) published a comprehensive review in Current Pharmaceutical Design examining the pharmacological activity and clinical use of polydeoxyribonucleotide (PDRN), with particular focus on the adenosine A2A receptor as the primary mediator of PDRN's therapeutic effects ^[1]. The review synthesized evidence from over two decades of preclinical and clinical research conducted primarily by the University of Messina research group and collaborating institutions. PDRN is a mixture of deoxyribonucleotide polymers with chain lengths of 50-1500 kDa, extracted from the sperm cells of Oncorhynchus mykiss (rainbow trout, previously classified as salmon trout) through a standardized extraction and purification process that yields a product free of proteins and peptides ^[1]. The review established that PDRN's pharmacological effects operate through two parallel mechanisms: A2A receptor agonism and nucleotide salvage pathway substrate supply, with the A2A pathway responsible for the anti-inflammatory and angiogenic effects that dominate PDRN's clinical profile ^[1][5].

Methods

This publication is a narrative review that aggregates findings from the authors' extensive body of preclinical research alongside published clinical evidence from multiple investigator groups ^[1]. The review examines evidence from in vitro studies (fibroblast, keratinocyte, and endothelial cell cultures), in vivo animal models (diabetic wound healing, skin flap ischemia, collagen-induced arthritis, thermal injury), and human clinical trials (wound healing, skin rejuvenation, orthopedic applications) ^[1][2][3][4]. The mechanistic evidence is organized around the A2A receptor pathway, with pharmacological confirmation provided through studies using the selective A2A receptor antagonist ZM241385, which blocks PDRN's effects and confirms receptor specificity ^[1][2][3].

Results

The review presents a cohesive body of evidence establishing the A2A receptor as the central mediator of PDRN's pharmacological activity ^[1]:

Anti-inflammatory mechanisms. PDRN binding to the A2A receptor activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP), which activates protein kinase A (PKA) ^[1]. PKA phosphorylates downstream targets that inhibit NF-kB nuclear translocation, the master transcription factor for inflammatory gene expression ^[1][2]. In experimental models, this translates to significant reductions in TNF-alpha (40-60% reduction), IL-6, IL-8, and other pro-inflammatory mediators ^[1][2]. In a collagen-induced arthritis model, PDRN treatment reduced clinical severity scores by approximately 50% and decreased inflammatory cytokine levels in joint tissue — effects that were completely abolished by co-administration of the A2A antagonist ZM241385, confirming receptor specificity ^[2].

Pro-angiogenic effects. PDRN upregulates vascular endothelial growth factor (VEGF) expression through the A2A-cAMP-PKA pathway, promoting new blood vessel formation in ischemic and damaged tissues ^[1][3][4]. In a genetically diabetic mouse wound model (db/db mice), PDRN treatment significantly accelerated wound closure, increased VEGF expression, and improved angiogenesis compared to vehicle controls ^[3]. In an experimental skin flap ischemia model, PDRN rescued flap viability by restoring blood flow through VEGF-mediated angiogenesis — again, an effect blocked by A2A receptor antagonism ^[4]. These findings are clinically relevant because impaired angiogenesis is a central mechanism in delayed wound healing, diabetic ulcers, and tissue ischemia ^[1].

Tissue regeneration. The A2A receptor pathway stimulates fibroblast proliferation and extracellular matrix synthesis through CREB (cAMP response element binding protein) activation, which upregulates procollagen gene transcription ^[1][5]. This mechanism operates in parallel with PDRN's role as a substrate for the nucleotide salvage pathway, which provides purine and pyrimidine building blocks for DNA synthesis in proliferating cells ^[1][5]. The dual mechanism — receptor-mediated signaling plus metabolic substrate supply — explains why PDRN produces a more robust regenerative response than either A2A receptor agonists or nucleotide supplements alone ^[1].

Pharmacological specificity. A critical element of the review is the consistent demonstration across multiple experimental models that PDRN's effects are abolished or significantly attenuated by the selective A2A receptor antagonist ZM241385 ^[1][2][3][4]. This pharmacological evidence elevates PDRN beyond a generic tissue supplement to a specific receptor-targeted agent with a defined mechanism of action. The A2A receptor is expressed on fibroblasts, keratinocytes, endothelial cells, and immune cells — which accounts for the breadth of PDRN's tissue effects ^[1].

Conclusion

Squadrito et al. establish PDRN as a pharmacologically active biological agent with a well-defined dual mechanism of action: A2A adenosine receptor agonism (driving anti-inflammatory, pro-angiogenic, and pro-regenerative signaling) and nucleotide salvage pathway supplementation (providing metabolic substrates for cellular proliferation) ^[1][5]. The A2A receptor pathway is the dominant mechanism underlying PDRN's clinical utility across wound healing, skin rejuvenation, and tissue repair applications ^[1]. The anti-inflammatory activity through NF-kB suppression is particularly significant for dermatological applications, where chronic low-grade inflammation (inflammaging) drives progressive collagen degradation and skin quality decline ^[1][2]. The comprehensive pharmacological characterization presented in this review provides a strong mechanistic foundation for PDRN's expanding clinical use and supports its classification as a biologically active therapeutic agent rather than a cosmetic ingredient ^[1][5].